Dietary DHA reduces downstream endocannabinoid and inflammatory gene expression and epididymal fat mass while improving aspects of glucose use in muscle in C57BL/6J mice

International Journal of Obesity

Volumn 40, Issue 1, 2016, Pages 129-137

  Kim, J ^a   Carlson, M E ^a,b   Kuchel, G A ^a   Newman, J W ^c,d   Watkins, B A ^a,d  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c U S DEPARTMENT OF AGRICULTURE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ARACHIDONATE 5 LIPOXYGENASE; DOCOSAHEXAENOIC ACID; ENDOCANNABINOID; GLUCOSE; MESSENGER RNA; OMEGA 3 FATTY ACID; CANNABINOID RECEPTOR AFFECTING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; C57BL 6 MOUSE; CONTROLLED STUDY; EPIDIDYMIS FAT; FAT MASS; GENE EXPRESSION; GENE PRODUCT; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; INVESTIGATIVE PROCEDURES; MALE; MOUSE; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; WESTERN BLOTTING; ADIPOSE TISSUE; ANIMAL; C57BL MOUSE; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIVER; METABOLISM; PATHOLOGY;

ADIPOSE TISSUE; ANIMALS; CANNABINOID RECEPTOR MODULATORS; DIET, HIGH-FAT; DOCOSAHEXAENOIC ACIDS; ENDOCANNABINOIDS; FATTY ACIDS, OMEGA-3; GLUCOSE; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL;

EID: 84953359460     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2015.135     Document Type: Article

References (57)

1. De Petrocellis L, Melck D, Bisogno T, Milone A, Di Marzo V. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience 1999; 92: 377-387.
2. Soderstrom K, Tian Q, Valenti M, Di Marzo V. Endocannabinoids link feeding state and auditory perception-related gene expression. J Neurosci 2004; 24: 10013-10021.
3. Piazza PV, Lafontan M, Girard J. Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system. Diabetes Metab 2007; 33: 97-107.
4. Howlett AC. Cannabinoid receptor signaling. Handb Exp Pharmacol 2005; 168: 53-79.
5. Howlett AC. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 1985; 27: 429-436.
6. Kaminski NE, Koh WS, Yang KH, Lee M, Kessler FK. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem Pharmacol 1994; 48: 1899-1908.
7. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 2006; 126: 177-187.
8. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
9. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-775.
10. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100.
11. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-R353.
12. Cavuoto P, McAinch AJ, Hatzinikolas G, Janovska A, Game P, Wittert GA. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 2007; 364: 105-110.
13. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005; 29: 183-187.
14. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91: 3171-3180.
15. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060.
16. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843.
17. Cota D. The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity. J Neuroendocrinol 2008; 20(suppl 1): 35-38.
18. Esposito I, Proto MC, Gazzerro P, Laezza C, Miele C, Alberobello AT et al. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 2008; 74: 1678-1686.
19. Eckardt K, Sell H, Taube A, Koenen M, Platzbecker B, Cramer A et al. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 2009; 52: 664-674.
20. Kim J, Carlson ME, Watkins BA. Docosahexaenoyl ethanolamide improves glucose uptake and alters endocannabinoid system gene expression in proliferating and differentiating C2C12 myoblasts. Front Physiol 2014; 5: 100.
21. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007; 92: 4810-4819.
22. Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A. Exercise activates the endocannabinoid system. Neuroreport 2003; 14: 2209-2211.
23. Yan ZC, Liu DY, Zhang LL, Shen CY, Ma QL, Cao TB et al. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun 2007; 354: 427-433.
24. Banni S, Carta G, Murru E, Cordeddu L, Giordano E, Sirigu AR et al. Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. Nutr Metab 2011; 8: 7.
25. Batetta B, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr 2009; 139: 1495-1501.
26. Watkins BA, Li Y, Seifert MF. Dietary ratio of n-6/n-3 PUFAs and docosahexaenoic acid: actions on bone mineral and serum biomarkers in ovariectomized rats. J Nutr Biochem 2006; 17: 282-289.
27. Li Y, Seifert MF, Lim SY, Salem N Jr, Watkins BA. Bone mineral content is positively correlated to n-3 fatty acids in the femur of growing rats. Br J Nutr 2010; 104: 674-685.
28. Grapov D, Adams SH, Pedersen TL, Garvey WT, Newman JW. Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids. PloS One 2012; 7: e48852.
29. Keenan AH, Pedersen TL, Fillaus K, Larson MK, Shearer GC, Newman JW. Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers. J Lipid Res 2012; 53: 1662-1669.
30. Nording ML, Yang J, Georgi K, Hegedus Karbowski C, German JB, Weiss RH et al. Individual variation in lipidomic profiles of healthy subjects in response to omega-3 Fatty acids. PloS One 2013; 8: e76575.
31. Funk WD, Ouellette M, Wright WE. Molecular biology of myogenic regulatory factors. Mol Biol Med 1991; 8: 185-195.
32. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 2003; 23: 2371-2382.
33. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 1993; 90: 7656-7660.
34. Baron AD, Brechtel G, Wallace P, Edelman SV. Rates and tissue sites of non-insulinand insulin-mediated glucose uptake in humans. Am J Physiol 1988; 255: E769-E774.
35. Watkins BA, Li Y, Allen KG, Hoffmann WE, Seifert MF. Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. J Nutr 2000; 130: 2274-2284.
36. Li Y, Greiner RS, Salem N Jr, Watkins BA. Impact of dietary n-3 FA deficiency on rat bone tissue FA composition. Lipids 2003; 38: 683-686.
37. Hutchins-Wiese HL, Li Y, Hannon K, Watkins BA. Hind limb suspension and longchain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle. J Nutr Biochem 2012; 23: 986-993.
38. Chong MF, Hodson L, Bickerton AS, Roberts R, Neville M, Karpe F et al. Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 d of high-carbohydrate feeding. Am J Clin Nutr 2008; 87: 817-823.
39. Peter A, Cegan A, Wagner S, Lehmann R, Stefan N, Konigsrainer A et al. Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios. Clin Chem 2009; 55: 2113-2120.
40. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-1351.
41. Sjogren P, Sierra-Johnson J, Gertow K, Rosell M, Vessby B, de Faire U et al. Fatty acid desaturases in human adipose tissue: relationships between gene expression, desaturation indexes and insulin resistance. Diabetologia 2008; 51: 328-335.
42. Bellenger J, Bellenger S, Clement L, Mandard S, Diot C, Poisson JP et al. A new hypotensive polyunsaturated fatty acid dietary combination regulates oleic acid accumulation by suppression of stearoyl CoA desaturase 1 gene expression in the SHR model of genetic hypertension. FASEB J 2004; 18: 773-775.
43. Arnold C, Markovic M, Blossey K, Wallukat G, Fischer R, Dechend R et al. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids. J Biol Chem 2010; 285: 32720-32733.
44. Gladine C, Newman JW, Durand T, Pedersen TL, Galano JM, Demougeot C et al. Lipid profiling following intake of the omega 3 fatty acid DHA identifies the peroxidized metabolites F4-neuroprostanes as the best predictors of atherosclerosis prevention. PLoS One 2014; 9: e89393.
45. Alvheim AR, Malde MK, Osei-Hyiaman D, Lin YH, Pawlosky RJ, Madsen L et al. Dietary linoleic acid elevates endogenous 2-AG and anandamide and induces obesity. Obesity 2012; 20: 1984-1994.
46. Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci USA 2001; 98: 6402-6406.
47. Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA et al. Cannabinoid receptor-dependent and-independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and-negative prostate cancer cell lines. Carcinogenesis 2010; 31: 1584-1591.
48. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-9617.
49. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the antiinflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005; 67: 15-19.
50. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 1997; 40: 659-667.
51. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-289.
52. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-10703.
53. Spoto B, Fezza F, Parlongo G, Battista N, Sgro E, Gasperi V et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie 2006; 88: 1889-1897.
54. Ahmadian M, Abbott MJ, Tang T, Hudak CS, Kim Y, Bruss M et al. Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. Cell Metab 2011; 13: 739-748.
55. Buhl ES, Jessen N, Pold R, Ledet T, Flyvbjerg A, Pedersen SB et al. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 2002; 51: 2199-2206.
56. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005; 280: 25196-25201.
57. Bermudez-Silva FJ, Sanchez-Vera I, Suarez J, Serrano A, Fuentes E, Juan-Pico P et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol 2007; 565: 207-211.